# Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

> **NCT04524390** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Biliary Atresia

## Interventions

- **DRUG:** Maralixibat
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04524390
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2023-11-07
- **Final completion:** 2024-02-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524390, "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04524390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*